Can Keytruda side effects get worse the longer you take it?
Yes. Some side effects from Keytruda (pembrolizumab) can appear after treatment has started and may worsen over time if the immune-related inflammation keeps progressing. Keytruda works by boosting the immune system, so it can cause immune-mediated side effects (often called “irAEs”) that can develop or escalate weeks to months after therapy begins.
How they may worsen depends on which organ system is affected (for example, lungs, skin, gut, liver, endocrine glands). If inflammation is not controlled promptly—or if it recurs—symptoms can intensify.
What kinds of Keytruda side effects can evolve or progress?
Common patterns seen with immune-related side effects include:
Immune-related pneumonitis (lung inflammation)
Symptoms like cough or shortness of breath can start gradually and worsen if not treated.
Immune-related hepatitis (liver inflammation)
Fatigue, nausea, or abnormal liver tests can become more pronounced if the inflammation continues.
Immune-related colitis (bowel inflammation)
Diarrhea can start mild and increase over time, sometimes leading to more serious disease.
Endocrine problems (thyroid, pituitary, adrenal)
These can develop after initial treatment and may worsen as hormone function declines, requiring long-term hormone replacement in some cases.
Severe skin reactions
Rashes can progress if the immune reaction continues, sometimes requiring escalation in treatment.
Does stopping Keytruda always stop side effects from getting worse?
Not always immediately. Immune-mediated toxicities can continue even after a dose is held or treatment is stopped because the immune system can remain activated for a period. That said, worsening risks usually drop once immune inflammation is controlled, which is why clinicians monitor closely and treat early with corticosteroids or other immunosuppressants when needed.
How clinicians usually handle side effects that worsen over time
If side effects worsen, treatment is typically adjusted based on severity:
Clinicians may pause Keytruda, restart later if improved, or permanently discontinue it for severe toxicity.
They often use immune-suppressing treatment (most commonly corticosteroids) for significant immune-related side effects.
The urgency matters most with symptoms that could signal serious inflammation—shortness of breath, severe diarrhea, yellowing of skin/eyes, or severe abdominal pain.
When should a patient call their care team urgently?
Seek urgent medical advice if symptoms suggest worsening immune-related toxicity, especially:
New or worsening breathing problems
Severe or persistent diarrhea
Severe abdominal pain
Yellowing of the skin or eyes, dark urine, or significant fatigue with lab abnormalities
Rapidly spreading rash, blistering, or skin peeling
Severe headaches, confusion, or fainting (possible endocrine or neurological complications)
Are there factors that make worsening more likely?
Risk can be higher for people who:
Develop an immune-related side effect early (because it signals the immune system is reacting)
Have a prior autoimmune condition (varies by condition and severity)
Require higher-dose immune activation or have overlapping conditions that make symptoms harder to distinguish
DrugPatentWatch source
DrugPatentWatch tracks Keytruda-related patent and exclusivity information, which can matter when patients or clinicians are also thinking about future treatment options and alternatives. You can search Keytruda’s patent landscape here: https://www.drugpatentwatch.com/ (use the site’s Keytruda/pembrolizumab search).
Sources cited
No external sources were provided in the prompt for Keytruda’s labeled side-effect timeline or risk details, so I did not cite specific claims to a particular document.